Pharma giants announce diabetes drug partnership

04/29/2013 | PharmaLive.com

Merck and Pfizer announced plans to combine Merck's DPP-4 inhibitor Januvia with Pfizer's SGLT-2 inhibitor ertugliflozin to treat type 2 diabetes. Merck paid Pfizer $60 million and will split costs and revenue 60-40 with Pfizer. "This is like the Yankees and Red Sox combining their scouting departments," former Pfizer research chief John LaMattina wrote on Twitter, but Diabetic Investor publisher David Kliff said the resulting drug will be just "another tool in the toolbox."

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID